Noxopharm Quote - NOX

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.105

Bid

0.105

Offer

0.11

Volume

5,296

0.10 Day's Range 0.105

0.051 52 Week Range 0.15

Market Cap

30.685M

Previous Close

0.10

Open

0.10

Last Trade

5000

0.105

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

310,882

Shares Outstanding

292,237,950

Dividend Yield

PE Ratio

-8.20

Earnings Per Share (EPS)

-0.01

Revenue

2.4M

Net Profit

-3.58M

Sector

Drugs And Proprietary-whsl

Industry

Drugs And Proprietary-whsl

Website

www.noxopharm.com

Headquarters

Sydney, New South Wales, Aus

Founded

Noxopharm Limited is listed in the Drugs And Proprietary-whsl sector of the Australian Stock Exchange with ticker NOX. The last closing price for Noxopharm was AUD0.10. Over the last year, Noxopharm shares have traded in a share price range of AUD 0.051 to AUD 0.15.

Noxopharm currently has 292,237,950 shares in issue. The market capitalisation of Noxopharm is AUD29.22 million. Noxopharm has a price to earnings ratio (PE ratio) of -8.20.

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda®, its lead oncology drug candidate, for...

Sarcoma Trial for New Cancer Treatment Begins at City of Hope in Los Angeles

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced its Phase 1 CEP-2 sarcoma trial is underway with a first patient enrolled and dosed at City of Hope in Los...

Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research

Exclusive deal for cutting-edge RNA technology in drug discovery and vaccines Australian clinical-stage drug development company Noxopharm (ASX:NOX) has in-licensed novel RNA technology...

Noxopharm Announces DARRT-2 Clinical Trial in U.S.

Experimental Immunotherapy Cancer Treatment Enters Phase 2 Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced its DARRT-2 Phase 2 clinical trial has commenced...

ノクソファームの前臨床データがCOVID-19の治療におけるイドロノキシルの抗炎症作用をさらに裏付ける

（ビジネスワイヤ） -- オーストラリアの臨床段階医薬品開発企業であるノクソファーム（ASX:NOX）は、治験薬の抗がん剤でビヨンダの有効成分となっているイドロノキシルが、早期COVID-19の治療における抗炎症薬...

Les données précliniques de Noxopharm confirment le rôle anti-inflammatoire de l’idronoxil dans le cadre du traitement de la COVID-19

La société australienne de développement de médicaments de stade clinique, Noxopharm (ASX : NOX) a publié des données précliniques qui viennent confirmer le rôle de l’idronoxil, médicament...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.005	-4.54545454545	0.11	0.125	0.097	211875	0.10302102	DE
4	-0.025	-19.2307692308	0.13	0.15	0.097	256416	0.11890611	DE
12	0.0025	2.43902439024	0.1025	0.15	0.09	310882	0.11523209	DE
26	0.034	47.8873239437	0.071	0.15	0.066	248539	0.10387204	DE
52	-0.005	-4.54545454545	0.11	0.15	0.051	210868	0.09272144	DE
156	-0.39	-78.7878787879	0.495	0.495	0.033	356989	0.14279762	DE
260	-0.25	-70.4225352113	0.355	0.99	0.033	514390	0.33827163	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
OECROrbital Corporation Limited	AUD 0.002 (100.00%)	6.95k
VPRVolt Group Ltd	AUD 0.0015 (50.00%)	3.24M
EWCEnergy World Corporation Ltd	AUD 0.023 (43.75%)	2.96M
PCLOPancontinental Energy NL	AUD 0.01 (42.86%)	3M
RMLResolution Minerals Ltd	AUD 0.002 (33.33%)	54.04k
ADNOCAndromeda Metals Limited	AUD 0.001 (-50.00%)	10.75M
RBRRBR Group Limited	AUD 0.001 (-50.00%)	5M
MTLMantle Minerals Limited	AUD 0.001 (-33.33%)	5.48M
EUROEuropean Lithium Limited	AUD 0.004 (-33.33%)	250k
ARDOArgent Minerals Ltd	AUD 0.002 (-33.33%)	1.41M
OVTOvanti Ltd	AUD 0.024 (-7.69%)	77.18M
CDECodeifai Ltd	AUD 0.001 (0.00%)	70.55M
SYASayona Mining Limited	AUD 0.035 (2.94%)	57.28M
PLSPilbara Minerals Limited	AUD 2.60 (-5.45%)	55.05M
TMKTMK Energy Ltd	AUD 0.0025 (25.00%)	46.43M